Investor sentiment has been adversely affected by worries regarding the company’s drug pipeline. Nonetheless, we believe PFE ...

Those who invested in Pfizer three years ago and hung on are not thrilled. They would have done much better with a simple S&P ...

Paxlovid is an antiviral combination therapy that can reduce the risk of COVID-19 causing severe illness, hospitalization and ...

And better still, healthy and growing dividend-paying stocks tend to increase their payouts over time. Pfizer's total annual ...

The U.S. National Institutes of Health said it launched mid-stage clinical trials to test at least four treatments, including Pfizer's antiviral Covid-19 pill Paxlovid, as potential therapies for ...

Pfizer said its full-year profit should benefit from cost cuts across its research and manufacturing operations after posting ...

People who took Pfizer’s antiviral treatment Paxlovid shortly after infection saw a 26% lower risk of long Covid compared with those who didn’t, the study said.

Pharmaceutical major recorded a revenue jump to $14.65 billion, exceeding the market expectations. The company also raised ...

Pfizer reported a dip in profits Tuesday, driven partly by lower sales of Covid-19 therapeutic drug Paxlovid, as it maintained a 2025 forecast that does not include potential tariff effects.

Covid-19 treatment pill Paxlovid is seen in a box, at Misericordia hospital in Grosseto, Italy, Feb. 8, 2022.

Biopharmaceutical company Pfizer will manufacture materials for the antiviral drug Paxlovid in Kalamazoo, Mich., after a $120 million investment for the treatment's first stateside factory.

COVID-19 is rising in prevalence in many states nationally following the July 4 holiday week, but the role of the main therapy to treat it — the antiviral drug Paxlovid — is less clear ...